Drugs for obstructive airway diseases

Key figures
Data
Graphics
Comments

PRESCRIBERS
Main prescribers: General practitioners	72.62%
INSURED CONSUMERS
% of insured consumers	14.18%
Median age	48 years
Max/min ratio of the median age (by district)	1.18
Percentage of women	53.50%
Ratio Preferential scheme/General scheme	1.20
Coefficient of variation (2022)	17.70
Max/min ratio of % of insured consumers (by district)	1.83
CONSUMPTION
Annual consumption (DDD)	237,776,236
Consumption of DDD (per 100,000 insured persons)	2,066,020.52
% DDD issued outside the insurance (approximate)	3.56%
Average annual consumption per insured consumer (DDD)	145.73
% of insured consumers with > 3 times the average consumption	7,78%
Coefficient of variation 2013-2015	10.65
Coefficient of variation 2020-2022	13.11
Trend 2013-2022	-0.74%
Trend 2013-2019	-0.62%
Trend 2019-2022	-0.99%
DIRECT EXPENDITURE (DDD)
Annual expenditure charged to the insurance	235,529,824€
Average annual expenditure per insured person	20.47 €
Average patient share per insured consumer	12.58%
Max/min ratio of expenditure per insured person (by disctrict)	1.48
% “Low-cost” medication	41.69%
Trend 2013-2022	1.92%
Trend 2019-2022	5.17%

On this table, when a statistical test has been performed, the data showing a significant difference is displayed on an yellow background, otherwise on a grey background.

+ - ATC codes selected for analysis Click to collapse

CODES (ATC-5)	LABELS
R03AB	NON-SELECTIVE BETA-ADRENORECEPTOR AGONISTS
R03AC	SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS
R03AK	ADRENERGICS AND OTHER DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
R03AL	ADRENERGICS IN COMBINATION WITH ANTICHOLINERGICS
R03BA	GLUCOCORTICOIDS
R03BB	ANTICHOLINERGICS
R03BC	ANTIALLERGIC AGENTS, EXCL. CORTICOSTEROIDS
R03CA	ALPHA- AND BETA-ADRENORECEPTOR AGONISTS
R03CC	SELECTIVE BETA-2-ADRENORECEPTOR AGONISTS
R03DA	XANTHINES
R03DC	LEUKOTRIENE RECEPTOR ANTAGONISTS
R03DX	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES